Orum Therapeutics rakes in $84m Series B

Orum Therapeutics, a developer of targeted protein degraders to treat cancer, has raised $84 million in Series B financing.

24 June 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles